Advertisement

Topics

Latest "Zenobia Therapeutics, Inc." News Stories

09:51 EDT 22nd October 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics, Inc. for you to read. Along with our medical data and news we also list Zenobia Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics, Inc. Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 1–25 of 8,300+

Saturday 21st October 2017

AntiInflammatory TherapeuticsGlobal Market Status and Trend Report 20132023 [Report Updated: 16102017] Prices from USD $2480

Report SummaryAntiInflammatory TherapeuticsGlobal Market Status and Trend Report 20132023 offers a comprehensive analysis on AntiInflammatory Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key question...


Forge, Evotec expand existing alliance and launch of BLACKSMITH platform to discover broader range of therapeutics targeting metalloenzymes

Forge Therapeutics and Evotec have announced that the companies have expanded their existing strategic alliance and launched the BLACKSMITH platform to discover a broader range of therapeutics

#jobs #lifescience Multiple job openings in preclinical development of oligonucleotide drugs in Ractigen Therapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Multiple job openings in preclinical development of oligonucleotide drugs in Ractigen Therapeutics .Multiple job openings in preclinical development of oligonucleotide drugs in Ractigen Therapeutics Ractigen Therapeutics, founded by … Continue reading → Cet article...


Global RNAi for Therapeutic Market Analysis 20112017 and Forecast 20182023 [Report Updated: 07062017] Prices from USD $2980

SnapshotRNA interference RNAi is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including cosuppression, posttranscriptional gene silencing PTGS, and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all descri...

Global Hyaluronic Acid Based Dermal Fillers Market Analysis 20112017 and Forecast 20182023 [Report Updated: 31052017] Prices from USD $2980

SnapshotHyaluronic Acid Based Dermal Fillers are the product can be used to smooth away wrinkles and fine line, create fuller and more accentuated lips, and adding facial volume and contour.The global Hyaluronic Acid Based Dermal Fillers market will reach xxx Million USD in 2017. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market s...

Friday 20th October 2017

New study explores how herpes simplex virus may change during familial transmission

A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines.

Takeda, Hemoshear Therapeutics Enter Exclusive Drug Discovery Partnership in Liver Diseases

News HemoShear’s proprietary disease modeling platform applies principles of physiological blood flow to tissue derived from patients.

Immune Pharmaceuticals sells preferred shares, nets $16.5mm

Immune Pharmaceuticals Inc. (immune and inflammatory disease therapeutics) netted $16.5mm through the public sale of 18k unit...

Neothetics reverse merges with Evofem to create women’s health-focused company

Evofem Biosciences Inc. (non-hormonal female health therapeutics and contraceptives) and publicly traded spec pharma Neotheti...

AbbVie, Harpoon Therapeutics enter immuno-oncology collaboration

In its first collaboration since its founding in 2015, Harpoon Therapeutics is teaming up with AbbVie Inc. in the area of imm...

Cidara nets $19mm via PIPE

Cidara Therapeutics Inc. (developing anti-infectives and immunotherapies) netted $19mm through the private placement of 3.36m...

Public ADS sale nets $16.3mm for Akari

Akari Therapeutics PLC (treatments for rare blood, inflammatory, and immune diseases) netted $16.3mm through a public sale of...

Merck’s Mark DiNubile Joins BioAegis as Chief Medical Officer

Mark DiNubile has joined BioAegis Therapeutics as chief medical officer. DiNubile previously spent 16 years at Merck (NYSE: MRK), where his work focused on infectious diseases and vaccines. North Brunswick, NJ-based BioAegis is a clinical stage company developing treatments for inflammation and infection. The company’s lead drug is in Phase 2 studies as a potential […]

Audentes Therapeutics: Buy The Dip

Janssen and Arcturus Partner to Discover and Develop New Hepatitis B Drugs

SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) — Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work together to develop and commercialize …

Bayer makes 2 consumer health appointments

David SalazarThe company this week named Brenda Raphael SVP and general manager of its therapeutics business unit within the North American consumer health division, and named Jennifer Brendel VP and head of U.S. consumer health communications read more

Agilis Presents Data from its Gene Therapy Program for Angelman Syndrome

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today two presentations on its gene therapy program for Angelman syndrome (AS). A poster presentation entitled, “The A-BOM: Collaborating to identify patient-centered bio...

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business. ...

Agilis Biotherapeutics Announces Presentations on Angelman Syndrome Program at ESGCT and NORD Rare Disease Summit

Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today two presentations on its gene therapy program for Angelman syndrome (AS). A poster presentation entitled, “The A-BOM: Collaborating to identify patient-centered biomar...

Global Joint Repair Devices Market Research Report Forecast 20172022 [Report Updated: 18092017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Joint Repair Devices Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Joint Repair Devices industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elabora...

Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors

– Company to Host Conference Call on Thursday, November 2, 2017, at 12:30 pm ET to Discuss Results – Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the world’s largest pharma trade show and considered the leading international pharmaceutical business and networking event. The event will be held on October 24th – 2...

FDA gives orphan status to Pluristem's acute radiation syndrome drug

Pluristem Therapeutics' PLX-R18, which is being developed as a treatment for patients with acute radiation syndrome, was gran -More- 

Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases

Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection.

Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation

Press Release Nicox Enters Research Collaboration with  Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation   October 20, 2017 - release at 7:30 am CET Sophia Antipolis, France and Belfast, Northern Irelan


Quick Search
Advertisement
 

News Quicklinks